Researchers create artificial nanopores capable of detecting DNA Scientists have designed bottom-up peptides that can form artificial nanopores to identify and enable single molecule-sorting of genetic material in a lipid membrane, according to new research published in Nature Nanotechnology on November 22.Read More
Stem cell model reveals gene expression during development of hypothalamus Researchers created an in vitro stem cell model of the hypothalamus to study its development over different stages. In doing so, they identified several genes involved with bodily functions associated with the hypothalamus, including disorders related to sleep and reproduction, according to research published November 19 in Nature Communications.Read More
Myxoma virus enters as an exciting preclinical cancer immunotherapy platform A preclinical oncolytic viral vector platform under development was of interest at the recent Society for Immunotherapy of Cancer's 2021 annual meeting. OncoMyx Therapeutics' Chief Scientific Officer Leslie Sharp, PhD, spoke with ScienceBoard at the meeting.Read More
5 takeaways from SITC 2021 WASHINGTON, DC - The Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting November 10-14 was a successful gathering of research and clinical experts focused on the development of innovative cancer treatments. The ScienceBoard team was live onsite at the event. Editor in Chief Samantha Black, PhD, shared five takeaways from the meeting.Read More
Innovation and safety remain key amid shifting pandemic-impacted clinical trial protocols WASHINGTON, DC - During the pandemic, clinical trial execution for cancer therapies has been challenging, said Dr. Samit Hirawat, chief medical officer at Bristol Myers Squibb, at the Society for Immunotherapy of Cancer's 2021 annual meeting. Despite the challenges presented by the pandemic, Hirawat noted that stakeholders held patient safety and innovation as key priorities. Hirawat spoke with ScienceBoard onsite at the meeting.Read More
Where is the immunotherapy field headed after COVID-19? WASHINGTON, DC - Best known for his contributions to the Moderna COVID-19 vaccine, former Moderna chief medical officer, Dr. Tal Zaks, PhD, chaired a session on RNA vaccines at the Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting. Zaks shared his perspectives and hopeful outlook with ScienceBoard at the meeting.Read More
Is the accelerated approval process working for cancer immunotherapies? WASHINGTON, DC - Leveraging years of experience, Dr. Alessandra Cesano, PhD, who serves on the board of directors of the Society for Immunotherapy of Cancer (SITC), chaired a panel discussion on the accelerated approval process for cancer immunotherapies at the organization’s 2021 annual meeting. Cesano spoke with ScienceBoard at the meeting.Read More